Identification of prodrug, active drug, and metabolites in an ADEPT clinical study
| Autor: | C. J. Springer, Surinder K. Sharma, Kd Bagshawe, G. K. Poon |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Drug
medicine.drug_class media_common.quotation_subject medicine.medical_treatment Biophysics Pharmacology Monoclonal antibody Benzoates High-performance liquid chromatography Mass Spectrometry Mice Glutamates Pharmacokinetics medicine Animals Humans Prodrugs Chromatography High Pressure Liquid media_common Chemotherapy Chemistry Immunotoxins Antibodies Monoclonal Adept gamma-Glutamyl Hydrolase Cell Biology Prodrug Nitrogen Mustard Compounds Conjugate |
| Zdroj: | Cell Biophysics. 22:9-26 |
| ISSN: | 0163-4992 |
| Popis: | Antibody-directed enzyme prodrug therapy (ADEPT) involves two phases. The first is an antibody-enzyme conjugate that localizes to tumor. The second phase is a prodrug that is administered when the enzyme-conjugate has cleared from blood and other nontumor tissues. In the pilot-scale clinical trial, the prodrug has been measured--in the plasma of patients, by liquid chromatography (HPLC) and by liquid chromatography-mass spectrometry (LC-MS). Active drug has been detected and metabolites identified. An indirect measurement of enzyme-conjugate in the plasma of patients has also been developed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|